Therapeutic target analysis revealed subtype-specific patterns: immune checkpoints (CTLA4 and PDCD1) were upregulated in EcP, whereas MMP9 was dramatically downregulated in EcO. The gene discussed is PDCD1; the disease is endocrine-cerebro-osteodysplasia syndrome.